RxDoctor Payments Data

Nikolai Zdrale, MD

Family Medicine · Mt Lebanon, PANPI 1730344748

Payments from drug & device makers

$489in general payments, 2019–2025

Across 34 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$213
  • Lilly USA, LLC$79
  • AbbVie$53
  • Neurocrine Biosciences, Inc.$52
  • Acadia Pharmaceuticals Inc$28
  • Sunovion Pharmaceuticals Inc.$18
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$489100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$489 in reported general payments places this provider in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$122,566
Medicare patients
303
Services billed
1,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,144$333,737
IngrezzaValbenazine Tosylate75$293,129
AustedoDeutetrabenazine47$145,108
TrulicityDulaglutide114$97,122
XareltoRivaroxaban348$96,035
Trelegy ElliptaFluticasone/Umeclidin/Vilanter117$80,538
NuplazidPimavanserin Tartrate29$71,552
Dimethyl Fumarate12$69,604
Invega SustennaPaliperidone Palmitate22$67,825
JardianceEmpagliflozin215$65,106
Breo ElliptaFluticasone/Vilanterol93$40,692
MovantikNaloxegol Oxalate129$32,272
SantylCollagenase Clostridium Hist.60$28,475
DescovyEmtricitabine/Tenofov Alafenam12$27,951
XifaxanRifaximin27$26,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$52$293,12975 claims
Teva Pharmaceuticals USA, Inc.Austedo$213$145,10847 claims
Lilly USA, LLCTrulicity$79$97,122114 claims
Acadia Pharmaceuticals IncNuplazid$28$71,55229 claims
AbbVieRestasis$53$23,74650 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Mt Lebanon

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →